Foster & Motley Inc. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,475 shares of the medical research company's stock, valued at approximately $2,244,000.
Other large investors have also made changes to their positions in the company. Salomon & Ludwin LLC grew its position in Thermo Fisher Scientific by 1.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock worth $669,000 after buying an additional 17 shares during the period. Elyxium Wealth LLC raised its holdings in Thermo Fisher Scientific by 1.9% during the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock worth $613,000 after purchasing an additional 20 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. increased its position in shares of Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock valued at $1,436,000 after buying an additional 20 shares in the last quarter. Finally, Confluence Wealth Services Inc. raised its stake in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company's stock worth $2,487,000 after buying an additional 22 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.
Analysts Set New Price Targets
TMO has been the topic of a number of research reports. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target on the stock. Piper Sandler increased their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research report on Monday, July 27th. Royal Bank Of Canada lifted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. Finally, Barclays upped their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $619.41.
Get Our Latest Analysis on TMO
Insider Activity
In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $71,191,194.75. This represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 52,053 shares of company stock valued at $30,643,589 over the last quarter. 0.33% of the stock is owned by insiders.
Thermo Fisher Scientific Trading Up 4.3%
Shares of TMO opened at $614.32 on Thursday. The stock's fifty day simple moving average is $536.26 and its 200 day simple moving average is $508.51. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $227.14 billion, a P/E ratio of 33.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.85.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm's revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
See Also
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
